Biomedical Research and TherapyBiomedical Research and Therapyhttp://www.bmrat.org/Biomedical Research and Therapy10.15419/bmrat.v10i4.805Therapeutic Potential of Microbial Metabolites: New Insights and PerspectivesHashmiMuhammad Abu Talha Safdar10000-0002-1812-0591KhawarMuhammad Babarbabar.khawar@uon.edu.pk2NaseemRimsha10000-0003-3679-1257AfzalAli1ShahidNayab1AbbasiMuddasir Hassandr.muddasir@uo.edu.pk3SheikhNadeemnadeem.zool@pu.edu.pk1AfzalNimra1MukhtarMaryam4ShahzamanSara1HamidSyeda Eisha1HabibaUme5FarooqAdil6AshrafMuhammad Ahsan5MehmoodRabia1IdnanMuhammad7Molecular Medicine and Cancer Therapeutics Lab, Department of Zoology, Faculty of Science and Technology, University of Central Punjab, Lahore, PakistanApplied Molecular Biology & Biomedicine Lab, Department of Zoology, University of Narowal, Narowal, PakistanCell and Molecular Biology Lab, Institute of Zoology, University of the Punjab, Lahore, PakistanDepartment of Structural and Cell Biology, Tulane University, USADepartment of Zoology, University of Education, Lahore, PakistanDepartment of Zoology, University of Okara, Punjab, PakistanDepartment of wildlife & Ecology, University of Okara, Okara104 56385653Abstract
Microbes release important metabolites that regulate various physiological activities inside and outside of organisms. The human gastrointestinal tract is a reservoir of microbes that play important regulatory roles in modulating the immune system and numerous other physiological functions. Thus, there is substantial interest in these microbial products and their clinical significance. These microbial metabolites have shown promise as therapies for cancer, inflammation, neurological disorders, and many other diseases. Here, we discuss microbial metabolites with substantial therapeutic potential, including proteasome inhibitors, therapeutic enzymes, bacteriocins, polyamines, and flavonoids.
Therapies involving metabolites produced and released by microbes have received substantial attention from the scientific and medicinal community in recent decades. Microbial metabolites are microorganism-produced compounds with potential therapeutic applications. Microbial metabolites are being assessed as novel therapeutic tools for various diseases, including cancer and immune disorders1. The first therapeutic use of microbes to treat infection occurred during World War II after Alexander Fleming isolated penicillin in 19282. Currently, researchers are using different biological and chemical methods to study the biological effects of microbial metabolites on humans3. There is a growing demand for using substances generated from microorganisms in medicine, agriculture, the food industry, and scientific research4. Developing anticancer drugs with reduced side effects from the microbiome has been a research priority for many years. Researchers have discovered that natural products can help treat cancer, illness, infection, allergy, and many other diseases5, demonstrating that microorganisms are viable sources of therapeutics. Microbes associated with the human body impact pathophysiological processes, including metabolic disorders, mental disorders, and even cancer6. Actinomycetes produce 0.1% of known microbial secondary metabolites, Bacillus produce 7.0% and other bacteria produce 1–2%7. Other diseases, such as tuberculosis (TB), have long been treated using natural remedies derived from microbial secondary metabolites8. Currently, four drugs, isoniazid, rifampin, pyrazinamide, and streptomycin, are used to treat TB. The World Health Organization (WHO) plan for TB helps patients limit its spread worldwide. Microbial natural products benefit patients, avoiding injections and acting as alternatives to synthetic drugs and other regular therapies9. Microbial amino acids have been utilized in nutritional supplements and food for humans and animals. It is promising and economically advantageous to produce essential amino acids on an industrial scale using microbial metabolites10. Piericidins are a large class of microbial metabolites commonly formed by species of the genus Streptomyces and comprise a 4-pyridinol core skeleton with a methylated polyketide side chain11. Piericidin application has been developed over time. Streptomyces broth culture was screened in 1993 to assess the antitumor effects of piericidin as a novel phosphatidylinositol turnover inhibitor. Piericidins have been isolated from soil, water, and insect samples12. Here we summarize the main types of microbial metabolites that exhibit different therapeutic properties and can be potentially of clinical and therapeutic use. These metabolites are either secreted by microbes outside of the body or associated with the microbiome.
Biomimicry of Microbial Metabolites
The word biomimicry is derived from the Greek bios, meaning life, and mimesis, meaning imitation. Biomimicry approaches are frequently used in drug discovery. The novel approach of microbial metabolite imitation can increase the chemical repertoire of future pharmaceuticals. In medicine, biomimicry involves the development of homologs of host-endogenous molecules that target specific receptors and provide a desirable result13. The future development of pharmaceuticals will likely be broadened by the use of microbial metabolites that imitate promiscuous ligand–receptor interactions. Xenobiotic nuclear receptors, such as PXR and AhR, are prototypical host receptors with weak ligand interactions. Microbial metabolite mimicry using PXR and AhR as model xenobiotic receptors has been found to result in powerful and non-toxic treatments, mediating pathophysiological disorders involving these receptors. It is also plausible that these weaker receptor-ligand interactions have evolved to the host's benefit to avoid receptor overstimulation, which may have certain negative effects. Additionally, not all microbial metabolites are advantageous; some promote inflammation and cancer development13. Microbial metabolite mimics with distinct antibacterial effect can be tested against intestinal bacteria in vitro or in consortia-inoculated germ-free animals to explore diversity control as a method for host disease control. Thus, mimicry enables the diversification of the microbiome and the upkeep of host health homeostasis by increasing the metabolite repertoire14. Kaempferol, a natural flavanol, has anti-arthritis properties, among other pharmacological effects. Intraperitoneal (20 mg kg-1 d-1) and intragastric (200 mg kg-1 d-1) kaempferol delivery has been assessed for efficacy and mechanistic action in collagen-induced arthritis (CIA) mice. Kaempferol retained in the gastrointestinal tract diversified the microbiota. These findings support the idea that microbiome diversity contributes to the therapeutic effect. Kaempferol mimics with strong microbial remodeling capabilities can be used for arthritis therapy15. Intestinal microorganisms may produce indole/indole-3-propionic acid, which, when activated by PXR, downregulates the TLR4-NF-B inflammatory pathway in mice; an indole/indole-3-propionic acid small-molecule mimic of PXR enhance receptor activation. Unlike other PXR xenobiotics, the small-molecules FKK5 and FKK6 mimic the natural indole metabolites, avoiding toxic effects16.
The path toward using microbial metabolites as potential therapeutics<italic id="emphasis-8"/>
Humans have used numerous conventional drugs formulated from herbs, fungi, and synthetic chemistry as pharmaceuticals for centuries16. These products have effectively cured ailments such as cancer17. However, due to the limitations of past pharmaceuticals in curing and treating novel medical problems, drug and pharmaceutical development has grown exponentially in the past five decades, replacing older drugs to eliminate severe side effects and improve efficacy. Scientists and researchers have become more interested in microbes and their products, and the positive findings in clinical studies evaluating microbial products have led companies and agencies to opt for these strategies in novel drug development18. Many strategies, such as metal-based compounds from microbes, enzymes, and proteasomes, have been targeted for their clinical and therapeutic significance (Table 1).
Microbial proteasome inhibitors
Proteosomes are the regulatory machinery that regulates the homeostatic conditions of the body by removing and degrading regulatory proteins. Many of these proteins play a substantial role in developing immunity against pathogens19, 20. A proteosome of the TB-causing bacteria Mycobacterium tuberculosis was targeted by two small drugs, namely, MMV019838 and MMV687146. These drugs showed promise for curing TB and achieved better outcomes in in silico tests21. Proteosomes are Ntn-hydrolases (N-terminal nucleophiles) that require ATP to cleave amide bonds22, 23. Regulatory proteins such as CDK inhibitors, cyclins, and tumor suppressors are extremely vulnerable to this machinery if demonstrating abnormalities in structure or function. Proteosome Inhibitors (PIs) target proteosomes and affect their functionality19. Biophysical parameters, such as the local concentration of proteins and their binding affinities, are critical for the PI efficacy24. PIs enhance immune responses and control the growth of cancerous cells by preventing proteosomes from removing regulatory proteins19. PI development was initiated approximately fifteen years ago25; due to their immunosuppressive effects, PIs have demonstrated substantial potential in the development of drugs for inflammation, carcinoma, immune disorders, and muscular dystrophies25, 26. PIs have demonstrated particular efficacy for hematological malignancies, multiple myeloma, and multiple cell lymphoma27.
The ubiquinone–proteosome system (UPS) is a major protein turnover regulator in mammalian cells and can be effectively targeted by PIs to cure malignancies (Figure 1)28. Fellutamides are UPS inhibitors produced by Penicillium spp. and Aspergillus spp. in the gastrointestinal (GI) tract of Apogon endekataenia, a marine fish. Fellutamides are potently cytotoxic against in vitro a wide range of cancer cells, including sarcoma cells, fibroblasts, solid tumor cells, and human epidermoid carcinoma KB cells29. The mechanisms by which UPS functions within protein systems are shown in Figure 1.
<bold id="s-5abc40290859">Overview of inhibitors of UPS</bold>. An overview of the action mechanism of the UPS. UPS is the protein degradation mechanism consisting of three important components i.e., ubiquitinating enzymes (E1, E2, & E3), a 26S Proteosome, and deubiquitinating enzymes (DUBs). These components can be specifically targeted by different inhibitors as shown in the figure. These inhibitors are in their respective phases of trials and some have been shown to be efficacious in different conditions such as inflammations, cancers, and anti-microbial activities.
Lactacystin, synthesized by Streptomyces actinobacterium30, was the first-in-class PI discovered and incorporated into clinical research as a therapeutic31. Lactacystin effectively treats many diseases in animal models and is being evaluated in clinical trials. A rat model study used lactacystin to target UPS to address synaptic plasticity in Alzheimer’s disease (AD), successfully restoring synaptic tagging and capture (STC) and impairing activity-dependent synaptic plasticity in vitro and associative long-term memory in vivo. Thus, lactacystin is a potential therapy for AD32.
Belactosin (β-Lactone), mainly extracted from Streptococcus spp., is a PI with antitumor properties and potential bioactivity against viruses and bacteria. Marizomib, a naturally occurring β-Lactone extracted from the Salinispora tropica, has shown clinical and preclinical improvements in multiple myeloma33, 34.
<bold id="s-b26af9008991">The clinical significance of various microbial metabolites against molecular targets suggests their promising role in clinical translation of novel drugs</bold>
Sr.
Metabolite
Microbial Specie
Molecular targets
Clinical Significance
References
1
Prodigiosin
Serratia marcescens
Herpes simplex virus
(PG) is a natural red pigment secondary metabolite. That exhibit cellular targets altering apoptosis and proapoptotic anticancer effects
Serrawettin, which was isolated from the green potato rhizosphere, has potent antifungal properties. According to reports, serratia produce antibacterial chemicals and secondary metabolites such as the red pigment prodigiosin.
36
3
Ethyl acetate extract
Pseudoalteromonas rubra, Virgibacillus salaries
Nocardiopsis dassonvillei
The ethyl acetate was used to extract the active compounds that were tested for bacterial growth inhibitory activity against human clinical pathogens. The EA extract was prepared as described and analysed for its content of triptolide and tripdiolide, which are responsible for up to 90% of the bioactiviA extract.
37
4
Aminoglycosides (S-137-R)
Bacillus velezensis
Plasmid-mediated quinolone resistance
Aminoglycosides (S-137-R) used for the treatment of severe Gram-negative bacterial infections. Streptococcal and enterococcal endocarditis can be treated with some treatments for severe Pseudomonas aeruginosa infections, brucellosis, and in low dosages as a synergistic approach.
38
5
Methanolic pigment extract
Micrococcus sp.
Canthaxanthin (4′,4′-diketo-13-carotene)
It is still being done to screen bioactive substances to uncover new chemical structures for the methanolic pigment extract utilized in pharmaceuticals. Some substances have been developed as antibiotics, and they are essential for the survival and growth of microorganisms in bacterial populations or the ability to withstand nutritional stressors.
39
6
Germicidins, c-Actinorhodin
Streptomyces lanatus
Pyricularia oryzae
Some Streptomyces strains produce germicidins, which serve as autoregulators of spore germination.
40
7
Juglomycin A
Streptomyces achromogenes E91CS4
Streptozotocin
Juglomycins have bactericidal action against both Gram-positive and Gram-negative bacteria, as well as anticancer activity. There have been a few reports of racemic juglomycin syntheses
41
8
Acyl depsipeptide (ADEP)
Streptomyces hawaiiensis
ClpP serine protease
The caseinolytic protease (ClpP protease), the proteolytic centre of bacterial ATP-dependent proteases, was discovered to be the target of acyldepsipeptides (ADEPs), a new class of antibacterial chemical and its derivative. Treatment with ADEP lengthened Leptospira and slowed its growth kinetics.
42
9
Lipopeptide lipid 430
Algibacter sp. M09B557 and M09B04
Chloropid, Bacteroidetes
Human TLR2 transfected human embryonic kidney cells were triggered by Lipopeptide lipid 430, which also caused wild-type mice's blood CCL2 (MCP-1) levels to rise.
43
Microbial therapeutic enzymes
Enzymes have long been used in industry and were initially explored in the context of medical therapy in the 1950s, altering our perception of medicinal drugs and therapeutics. Due to their anti-inflammatory and anticancer effects, enzymes have been developed for several ailments, including cancer, AD, and hyperuricemia44.
Inflammation is an immune response mostly characterized by swelling at the site of homeostatic disturbance due to environmental agents such as pathogens, chemicals, or abrasions45. Conventional drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), have been used to overcome inflammation; however, such drugs are associated with several side effects, such as GI ulcers. Trends have shifted toward the use of microbial enzymes to overcome these problems, for example, serratiopeptidase, which has high efficacy in inflammation and almost no harmful effects46. In a study on bowel disease in mice, the gut microbiota schistosome-derived enzyme P28GST (28 kDa glutathione S-transferase) showed promising anti-inflammatory results in the colon, restoring the regulatory responses between T-helper 1 and T-helper 2 cells47.
Serratiopeptidase is produced by the gram-negative bacterium Serratia marcescens. Serratiopeptidase is a protease in the trypsin family and demonstrates highly anti-inflammatory proteolytic activity48, 49. Serratiopeptidase restores wound sites through an unusual mode of action, recruiting immune cells from the lymph nodes to the affected area to promote healing50. The efficacy of serratiopeptidase increases exponentially when used in combination with other drugs, such as NSAIDs48.
Another protease enzyme, collagenase, hydrolyzes collagen fibers50. Collagenase was used in enzymatic wound debridement prior to the discovery of its anti-inflammatory properties. Das et al. assessed the anti-inflammatory application of collagenase in mice in 2018. Wound-healing macrophages loaded with collagenase santyl ointment (CSO) were implanted into the mice, and anti-inflammatory cytokine production was increased in the CSO-treated groups, improving inflammatory wound healing51. Similarly, the suppression of pro-inflammatory cytokines was observed when simvastatin-loaded porous microspheres were injected into the tendons of the collagenase-induced Achilles tendinitis rats. The production of anti-inflammatory cytokines also increased52. Numerous other studies on the collagenase produced by Clostridium histolyticum have revealed that it is healthy, noninvasive, and safe in treating several pathological conditions53.
Superoxide dismutase is another clinically significant anti-inflammatory agent that can be derived from Cyanobacteria, such as Anabaena cylindrica, Plectonema borynarum, Nostoc commune, and Microcystis aerunginosa50.
L-asparaginase is a microbe-derived enzyme that can play an important role in the cure of cancer. Numerous molecules influence the proliferation of cancer cells and downregulate their growth50. L-asparaginase can be derived from Escherichia coli, Leucosporidium muscorum, Aspergillus terreus, Yersinia pseudotuberculosis, and Pseudomonas otitidis54, 55. L-asparaginase generates ammonia and aspartic acid by breaking down L-asparagine, which is the driver of its anti-cancerous ability. L-asparaginase is effective in treating lymphoblastic leukemia55.
Bacteriocins are the chemicals bacteria produce to eliminate competitors from ecological niches56 and are generally used in intra-specific interactions, for example, in competition for food and shelter57. Some bacteriocidins demonstrate anticancer activity with selective toxicity toward cancer cells58. Many bacteriocin molecules, such as Nisin A derived from Lactococcus lactis, are effective in head and neck squamous cell carcinoma (HNSCC) through inducing cell cycle arrest and blocking cell division59. Bacteriocins have also been found effective against breast cancer60. Bivocin H5C derived from Streptococcus bovis, Laterosporulin 10 derived from Brevibacillus sp, and Colicins A and E1 extracted from Escherichia coli also have antitumor properties61.
Arginine deiminase is an enzyme produced and secreted by Mycoplasma spp., such as M. hominis, M. arginine, and Pseudomonas furukawaii61. Arginine has shown encouraging antitumor and anticancer properties and can play a key role in the cure and treatment of numerous auxotrophic carcinomas through arginine depletion62. The absence of arginosuccinate synthetase 1 (ASS1) in most cancers is the key aspect of the functionality of ADI (arginine deiminase). ASSI is critical for L-arginine production; cancer cells take up L-arginine for growth. This dependence of the cells on external sources can be pivotal in the anti-cancerous activity of arginine deiminases63.
Microbial antibiotic resistance is rising; thus, there the development of novel therapies is urgent64, 65. Antibacterial drugs and therapeutics are a prominent focus for handling this increasing challenge and controlling human and animal pathogens57. Several strategies and therapeutics have been developed, such as bacteriocins and lysin enzymes, referred to as enzybiotics. Enzybiotics are microbial enzymes and products that hinder the growth of pathogenic bacteria. Since their discovery in 2001, enzybiotics have played a significant role in the development of microbial based antibacterial drugs to combat antibiotic resistance44.
Bacteriocins are the secondary metabolites bacteria produce to target competitors, hindering the growth and reproduction of other microbes66. Bacteriocins are antimicrobial peptides (AMPs) 12–100 amino acids in length67. AMPs have recently been found effective against human microbial pathogens derived from lactic acid bacteria (LAB), Lactobacillus68. Bacteriocins have shown great efficacy towards several microbe-borne diseases, including methicillin-resistant Streptococcus aureus (MRSA)69. LABs have been successfully employed in managing MRSA in clinical trials70. Another bacterial-produced TFnt, lysostaphin, is a bacteriocin that has demonstrated encouraging bactericidal activity against mutant Staphylococcus aureus strains71.
Endolysins are hydrolases that prevent the formation of the cell wall, cell membrane, envelope, and biofilm around antibiotic resistant strains of bacteria by lysing the peptidoglycan layer44, 72. Different endolysin enzymes have different mechanisms and target sites in Gram-positive and Gram-negative bacteria44. Many endolysins have shown efficacy in clinical trials. LysK-like endolysin derived from Staphylococcus spp. and LysSAP33 encoded by bacteriophage SAP33 have substantial lytic activity against the antibiotic-resistant Staphylococcus aureus, targeting biofilm formation73. Similarly, many endolysins, namely, Abtn-4, derived from a bacteriophage D2 (vB_AbaP_D2), have shown substantial therapeutic potential, preventing biofilm formation by multiple phage-resistant Gram-positive and Gram-negative bacteria (Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia, Enterococcus, and Salmonella). The aforementioned findings highlight the therapeutic potential of this endolysin74. Another important endolysin, LysAB54, was extracted from the phage p54 of the multi-drug resistant Acinetobacter baumannii and showed promising antibacterial activity this and other gram-negative bacteria, such as Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli75.
Other metabolites
Numerous other gut microbiome-derived metabolites also have immense therapeutic potential76. These metabolites play a substantial role in living organisms' biological machinery, influencing physiological, pathological, and metabolic activities and signaling pathways77. Gut microbial metabolites, such as short-chain fatty acids (SCFA) and many other organic compounds, have shown encouraging anticancer, brain modulation, anti-obesity, anti-bacterial, neurological, and mineral absorption properties78. These metabolites are very effective, especially for neurological diseases, including ASD, PD, AD, and neuroinflammation79, 80. Some other metabolites, such as TMA and TMAO, are also effective for cardiovascular diseases, including heart failure (72), hypertension81, and atherosclerosis82. Understanding the mechanisms of action of these metabolites will open doors for new therapeutic approaches81. Other such metabolites include TMAO, tryptophan, indoles, 4-ethylphenylesulfate, fatty acids, and protein-derived metabolites.
Protein-derived Metabolites
Protein-derived metabolites are functional, covalent protein modifications produced during or after protein digestion through endogenous, intrinsically reactive metabolites without the aid of enzymes83. Many protein-derived metabolites have been shown to be therapeutic. Taurine is a sulfur-containing β-amino acid and can be generated from cystine metabolism84, 85. Taurine has many important functions in animals' nervous system, muscles, kidneys, cardiovascular system, and immune system because of its anti-inflammatory and anti-oxidative effects85, 86. Taurine plays a vital role in maintaining homeostasis and many other physiological activities, such as gene expression and energy metabolism87, 88. Traumatic brain injury (TBI) is lethal, and inflammatory responses can result in death in other traumatic conditions. Taurine was administered to 32 patients with TBI conditions along with Standard Entera Meal. The levels of the inflammation biomarkers IL-6, IL-10, and TNF-α were recorded before and after the treatment, and serum IL-6 levels decreased significantly, showing the encouraging anti-inflammatory properties of taurine and its potential clinical use89. Taurolidine (TRD) is a taurine N-methylol derivative that exerts bactericidal and anti-inflammatory effects by inhibiting proinflammatory cytokines, such as IL-6, IL-8, and IL-1β90.
Imidazole propionate is another protein-derived microbial metabolite produced in the gut microbiome through histidine metabolism and is closely linked with glucose metabolism91, 92. Imidazole propionate disrupts glucose metabolism and causes several diseases, including type 2 diabetes and hypertension93, 94. T2D has been found to be closely associated with elevated imidazole propionate, which alters histidine metabolism and impairs glucose metabolism and insulin signaling by activating Mtor1, p38γ, and S6K1 signaling92. Imidazole propionate is a potential activator of p38γ map kinase, inhibiting metformin activity95, and is associated with increased pro-inflammatory cytokines that cause gastrointestinal inflammation and inflammatory bowel disease93.
Microbiota-associated polyamines are organic cations produced by the gut microbiota organisms, such as Clostridia96. These polyamines are derived from arginine-containing proteins97 and are involved in numerous metabolic and cellular activities, including cell growth and differentiation and the production of DNA, RNA, and several proteins96. Many polyamines are also uremic toxins that hasten the progression of renal fibrosis and uremia98. However, polyamines such as spermine can suppress inflammatory cytokine production and regulate NF-κB activation96. Spermine is also associated with prostate cancer (PCa); significantly decreased levels of spermine have been observed in PCa patients. Spermine levels are a marker of PCa, and understanding the mechanism of action of spermine may lead to its use as a therapeutic target99. Another polyamine, putrescine, is naturally produced in peri-ovulating women and decreased in women with age-related infertility, demonstrating the role of putrescine in ova production and its potential for improving ova quality as a treatment for infertile women of advanced maternal age100.
Flavonoids
Flavonoids are plant-based nutritional constituents with substantial health benefits101. Certain flavonoids may have hepatoprotective characteristics that reduce the risk of coronary heart disease102. Moreover, these flavonoids have anti-inflammatory and anticancer properties103. Flavonoids demonstrate structural and functional effects through enzyme inhibition, acting as antioxidants, damaging cells, triggering host defense mechanisms, and blocking virus cell attachment and penetration103, 104. As secondary plant metabolites, flavonoids constitute the majority of the non-energetic aspect of human nutrition. Most dietary flavonoids are O-glycosides and are primarily consumed as D-glucose; fermented foodstuffs such as wine, tempeh, and certain teas also contain flavonoids. The polarity of the flavonoid molecule increases with glycosylation, which is necessary for preservation in plant cell vacuoles105. Similarly, many GI tract microbial metabolites may be responsible for or contribute to quercetin's effect when taken orally since the flavonoid metabolites DHPA and 4-methylcatechol reduce arterial blood pressure106. The absorption, distribution, digestion, and elimination of flavonoids by the GI tract are critical processes affecting human health107. These features are influenced by how flavonoids interact with other dietary components, the host, the environment, and GI flora108. Flavonoids can target the microbiome, various GI tract cell types, and compounds present in luminal material107, 108, 109.
Bile acids
Bile acids are microbiological byproducts with potential therapeutic applications. The gut microbiota produces bile acids, which are crucial for dietary lipid solubilization110. The gut microbiota facilitates digestion and has been linked to diseases and health risks. Despite the considerable variation in gut microbiota composition, it is challenging to link intestinal microbiota patterns to health and nutrition because the gut microbiota has a high level of functional redundancy. Metabolomics has successfully identified gut-produced microbial metabolites that may be significant mediators of diet-induced host–microbial interaction in several studies. Among the metabolites derived from nutrition are short-chain fatty acids, secondary bile acids inferred from primary bile acids, microbial tryptophan catabolites that originate from proteolysis, imidazole propionate originating from histidine, and trimethylamine N-oxide111, 112. Bile acids can potentially be used to treat non-alcoholic fatty liver disease (NAFLD), cholestatic and metabolic liver diseases, infant jaundice, and other liver problems113, 114, 115, 116. NAFLD is the most frequent chronic liver disease worldwide115. The link between the gut microbiota & NAFLD has been widely researched. The gut microbiota controls NAFLD by fermenting undigested foodstuff, interacting with intestinal mucosal immune system, and altering intestinal barrier function, leading to signaling changes117. Microbial metabolites, including SCFAs, TMAO, BAs, endogenous ethanol, and indole, play important roles in NAFLD regulation. However, changes in microbial metabolites in NAFLD are undeniable. Microbial metabolites impact the signaling pathway in the stomach and the liver, which is distant from the gut117, 118. Microbes, in part, control the host's immune system by generating metabolites. An increasing body of research suggests that some microbial metabolites affect the immune system significantly through host receptors and other target molecules. P2X7, GPR41, GPR43, GPR109A, aryl hydrocarbon receptor precursor (AhR), farnesoid X receptor (FXR), PXR, and TGR5 are some of the metabolite-specific receptors expressed by immune cells119, 120, 121. Changes in food, bodily functions, and the immune system produce a range of signals from microbial metabolites and their receptors. Gut bacteria produce many lipid-modifying and metabolizing enzymes. For instance, polyunsaturated fatty acids are transformed into hydroxy fatty acids by gut bacteria such as Lactobacillus plantarum, which also encodes the enzymes that saturate polyunsaturated fatty acids122.
Polyamines
Polyamines are polycationic compounds with over two amino groups that are biosynthesized from ornithine and arginine. Polyamines, primarily putrescine, spermidine, and spermine, are abundant in the digestive system and are derived from food or biosynthesized by the host and bacteria. Polyamines are chiefly produced within the host by arginase 1 (which converts l-arginine to l-ornithine), ornithine decarboxylase (ODC), which metabolizes ornithine to putrescine, and enzymes that catalysis spermidine, putrescine, and spermine interconversion. In contrary to host polyamine metabolism, bacteria create polyamines using constitutive or inducible amino acid decarboxylases. Polyamines play an important role in cell proliferation, immune system activation, and cell differentiation. Polyamines are crucial during the cell development; a low content of polyamines inside the cell has been associated with cell growth abnormalities. Increased amounts of polyamines are needed by tumor cells relative to normal cells to sustain fast development; increased polyamine concentrations are observed in blood/urine samples from cancer patients relative to those in samples from healthy and normal individuals. Dysregulation of polyamine metabolism in the host or gut bacteria potentially contributes to colorectal cancer (CRC)123. Polyamines in the gut includes cadaverine, putrescine, and spermidine, although bacteria can produce other polyamines. Polyamine pathway enzymes have been found in various organisms. However, only a few species have been functionally characterized in terms of polyamine production. Polyamines are produced, accumulated, or required/used by Staphylococcus aureus, Haemophilus influenzae, E. coli, Enterococcus faecalis, Neisseria flava, and Vibrio cholera. Cadaverine is a lysine decarboxylation product produced by the bacterium enzymes LdcC and CadA. Cadaverine can be produced by humans and microorganisms. Cadaverine biosynthetic enzymes are also found in Streptococcus and Escherichia coli. Polyamine metabolism is dysregulated in pancreatic adenocarcinoma. The fact that modification of the polyamine cycle can amplify or alleviate the effects of traditional cytostatic therapy emphasizes the functional importance of polyamine production in (human) pancreatic cancer124.
<bold id="s-d38e2475b724">Role of TMAO</bold>. TMAO derived from the microbiome has a major role in controlling and regulating major blood and cardiovascular conditions. Increased levels of TMAO have negative effects including inflammation, increased risks of thrombosis, and disturbed glucose metabolism which leads to worsened health conditions; obesity, atherosclerosis CRC and CKD.
Tri-methylamine N-Oxide
Trimethylamine N-Oxide is an osmolyte and a metabolite produced in the gut microbiome and is generated from dietary choline, betaine, and L-carnitine125, 126 crucial for stabilizing protein structures in the presence of urea126. Several studies have shown that high circulating blood levels of TMAO are associated with the development of many chronic diseases, including cardiovascular diseases (CVD), atherosclerosis127, obesity (potentially)128, diabetes, colorectal cancer129, acute kidney disease (AKD) (Figure 2)130, and neurological disorders involving synaptic plasticity131, 132. Since TMAO plays a significant role in heart failure (HF) pathogenesis, one of several cardiovascular diseases (CVDs) caused by vascular inflammation, it can serve as an early and timely prognostic biomarker before HF becomes critical81, 133, 134. This inflammatory response associated with TMAO is also seen in conditions such as psoriatic arthritis (PsA). In a study conducted on 38 PsA patients, TMAO and other chemicals, such as Trimethylamine (TMA), choline, and carnitine, were found to be involved in inflammation. Thus targeting TMAO is a potential treatment for PsA135. In another in vitro study of vascular smooth muscle cells (VSMC) from rats and humans, TMAO was found to play a substantial role in the development of inflammatory responses; the Nox4-PRMT5-VCAM-1 pathway was revealed as a potential target for resolving this condition136. Recently, a study of 48 patients with preeclampsia (PE) revealed, by analyzing fecal matter plasma lipopolysaccharide (LPS) and Trimethylamine N-Oxide (TMAO) and in comparison with healthy controls, that elevated LPS and TMAO are present in PE patients137.
Fatty Acids
Short-chain fatty acids are the fermentation products of some gut-microbiome bacteria produced from non-digestible carbohydrates (NDCs)138. The most common SCFA-producing bacteria species are Anaerostipes caccae, Bacteroides eggerthii, and Clostridial spp.139. Therapeutically, SCFAs are important because have substantial anti-obesity, anti-inflammatory, and anti-diabetic potential140. Numerous SCFAs, such as valproic acid, acetate, butyrate, and propionate, hold immense therapeutic potential. Valproic acid (VPA) is an anti-convulsant and anti-epileptic SCFA with applications in many neurological disorders, including autism, epilepsy, migraine, and bipolar disorder141, 142. VPA also has anticancer activities143. VPA (3 μM) in combination with arsenic trioxide (ATO) (3 μM) showed synergistic anticancer effects in NCI-H460 and NCI-H1299 lung cancer cells in vivo and in vitro141. VPA has also shown antioxidant, anti-inflammatory, and antilipidemic properties in a female mouse model with type 1 diabetes. Wistar Rats with type 2 diabetes have also been treated with VPA (100, 300, and 600 mg/kg body weight) and metformin (100 mg/kg body weight), revealing anti-diabetic and pro-antioxidant effects144. Butyrate, another very important SCFA metabolite, is synthesized by gut microbiota and recognized as a very critical mediator in the regulation of whole-body energy metabolism145, particularly functioning as an important nutrient source for colonocytes, influencing their differentiation and growth146. Decreased butyrate levels have been observed in patients with ulcerative colitis (UC), leading to inflammation in the intestinal mucosa. Later it was discovered that butyrate downregulates the expression of genes involved in the inflammatory pathways147.
Long chain fatty acids (LCFA) are also therapeutically important. Omega-3 fatty acid (O3FA) is an important long-chain fatty acid not synthesized by the body. It is of great therapeutic interest due to its anti-inflammatory148, antineoplastic149, antithrombotic, insulin resistance, antiarrhythmic150, neuroprotective151, and immunomodulatory152 effects. Eicosatetraenoic acid (EPA) is one of the two main types of O3FA. It has the potential to control the signs and symptoms of depression. Previously, the brain was thought to contain very little or no EPA; however, EPA was recently found to penetrate the blood-brain barrier, where it is immediately esterified into phospholipids; thus, EPA does not build up in the brain and is instead found in at low levels in microglia. Randomized clinical trials are required to demonstrate the therapeutic potential of EPA in combatting major depression153. Recent studies have also demonstrated that EPA is essential for normal brain function. In controlled trials conducted on 92 children (aged 6–12) with attention deficit hyperactivity disorder (ADHD), in comparison with the placebo, high doses of EPA (1.2 g) improved overall focused attention and vigilance. Thus, EPA treatment may improve cognitive symptoms in ADHD-affected youth154. EPA has also shown anti-inflammatory effects155.
Conjugated linoleic acid (CLA) is another naturally occurring LCFA with substantial therapeutic potential due to its anti-carcinogenic, anti-atherosclerosis, and anti-obesogenic properties156. The therapeutic potential of CLA in cancer has been demonstrated in several animal and cellular models studies; clinical trials of CLA for breast cancer and prostate cancer have also been performed157.
4-Ethylephenylesulfate (4-EPS)
4-Ethylephenylesulfate (4-EPS) is a gut-microbiome-derived metabolite considered a uremic toxin158, 159. Elevated levels of 4-EPS have been observed during the atypical neurodevelopment of neuronal tissues in mice. Similarly, 4-EPS entered the brain in another mouse study and induced unusual brain activity and behaviors. In ex vivo culture, this disturbance of brain activity and behavior patterns was due to the decreased interaction between neuronal cells and oligodendrocytes due to impaired maturation. This impaired activity in mice could be cured by the pharmacological differentiation of oligodendrocytes, demonstrating the toxic effects of 4-EPS on behavior. These gut–brain interactions due to metabolites can be a potential target in treating complex behavior diseases including, autism spectrum disorder (ASD)76, 159. Similarly, higher levels of 4-EPS have been reported in the maternal immune activation (MIA) ASD mouse model, and this increased level of 4-EPS was controlled by the administration of Bacteroides fragilis. Axial Biotherapeutics also observed similar elevated concentrations in children with ASD160.
Conclusion
Numerous studies demonstrate the broad potential of microbial metabolites in the treatment of multiple diseases, especially those for which conventional therapies have failed; thus, these metabolites may represent the future of the drug and pharmaceutical industries. The broader efficacy of microbial metabolite therapies remains debatable, and more studies and clinical trials are required. However, previous small-scale studies indicate these therapies are potentially highly effective. Further investigation into microbial metabolites will allow their use to become more common beyond clinical trials. The resulting treatments will likely be comfortably incorporated into approaches for various diseases.
The authors are thankful to the Vice Chancellor, University of Narowal, Narowal, Pakistan for providing the support for the accomplishment of this manuscript.
Author’s contributions
Muhammad Babar Khawar, Muddasir Hassan Abbasi, And Nadeem Sheikh contributed to the study conception and design. Literature Search, data collection and visualization were performed by Ali Afzal, Muhammad Abu Talha Safdar Hashmi, Rimsha Naseem, Nayab Shahid, Adil Farooq, Maryam Mukhtar, Muhammad Ahsan Ashraf, and Syeda Eisha Hamid. The first draft of the manuscript was written by Muhammad Abu Talha Safdar Hashmi, Rimsha Naseem, Nayab Shahid, Rabia Mehmood, and Ali Afzal. Sara Shahzaman, Syeda Eisha Hamid, Muhammad Idnan and Ume Habiba revised the final version of the manuscript. All authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesLuuM.VisekrunaA.Microbial metabolites: novel therapeutic tools for boosting cancer therapiesTrends in Cell Biology2021311187351879-308810.1016/j.tcb.2021.08.00534538658TanS.Y.TatsumuraY.Alexander Fleming (1881-1955): discoverer of penicillinSingapore Medical Journal201556736672737-593510.11622/smedj.201510526243971AbdelghaniZ.HouraniN.ZaidanZ.DbaiboG.MradM.Hage-SleimanR.Therapeutic applications and biological activities of bacterial bioactive extractsArchives of Microbiology202120384755761432-072X10.1007/s00203-021-02505-134370077DanovaroR.CorinaldesiC.Dell'AnnoA.RastelliE.Potential impact of global climate change on benthic deep-sea microbesFEMS Microbiology Letters2017364231574-696810.1093/femsle/fnx21429045616KovácsT.MikóE.VidaA.Seb\HoÉ.TothJ.CsonkaT.Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptorsScientific Reports20199113002045-232210.1038/s41598-018-37664-730718646MaruvadaP.LeoneV.KaplanL.M.ChangE.B.The human microbiome and obesity: moving beyond associationsCell Host & Microbe2017225589991934-606910.1016/j.chom.2017.10.00529120742ZitvogelL.AyyoubM.RoutyB.KroemerG.Microbiome and anticancer immunosurveillanceCell20161652276871097-417210.1016/j.cell.2016.03.00127058662HussainA.RatherM.A.BhatZ.S.MajeedA.MaqboolM.ShahA.M.In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosisInternational Journal of Antimicrobial Agents201953149531872-791310.1016/j.ijantimicag.2018.09.01930267759DirlikovE.RaviglioneM.ScanoF.Global tuberculosis control: toward the 2015 targets and beyondAnnals of Internal Medicine201516315281539-370410.7326/M14-221025915859ZhouX.LiangZ.LiK.FangW.TianY.LuoX.Exploring the natural piericidins as anti-renal cell carcinoma agents targeting peroxiredoxin 1Journal of Medicinal Chemistry201962157058691520-480410.1021/acs.jmedchem.9b0059831298537AzadS.M.JinY.SerH.L.GohB.H.LeeL.H.ThawaiC.Biological insights into the piericidin family of microbial metabolitesJournal of Applied Microbiology20221322772841365-267210.1111/jam.1522234260807EnglT.KroissJ.KaiM.NechitayloT.Y.SvatošA.KaltenpothM.Evolutionary stability of antibiotic protection in a defensive symbiosisProceedings of the National Academy of Sciences of the United States of America20181159202091091-649010.1073/pnas.171979711529444867DvořákZ.SokolH.ManiS.Drug mimicry: promiscuous receptors PXR and AhR, and microbial metabolite interactions in the intestineTrends in Pharmacological Sciences2020411290081873-373510.1016/j.tips.2020.09.01333097284HaagL.M.SiegmundB.Exploring & exploiting our `other self' - does the microbiota hold the key to the future therapy in Crohn's?Best Practice & Research. Clinical Gastroenterology20142833994091532-191610.1016/j.bpg.2014.04.00124913380AaL.X.FeiF.QiQ.SunR.B.GuS.H.DiZ.Z.Rebalancing of the gut flora and microbial metabolism is responsible for the anti-arthritis effect of kaempferolActa Pharmacologica Sinica202041173811745-725410.1038/s41401-019-0279-831427695DvorakZ.KlapholzM.BurrisT.P.WillingB.P.GioielloA.PellicciariR.Weak microbial metabolites: A treasure trove for using biomimicry to discover and optimize drugsMolecular Pharmacology202098434391521-011110.1124/molpharm.120.00003532764096HuangM.LuJ.J.DingJ.Natural products in cancer therapy: past, present and futureNatural Products and Bioprospecting20211115132192-219510.1007/s13659-020-00293-733389713Puebla-BarraganS.ReidG.Forty-five-year evolution of probiotic therapyMicrobial Cell201964184962311-263810.15698/mic2019.04.67330956971MomoseI.KawadaM.The therapeutic potential of microbial proteasome inhibitorsInternational Immunopharmacology20163723301878-170510.1016/j.intimp.2015.11.01326589840KisselevA.F.Site-specific proteasome inhibitorsBiomolecules2021121542218-273X10.3390/biom1201005435053202TyagiR.SrivastavaM.JainP.PandeyR.P.AsthanaS.KumarD.Development of potential proteasome inhibitors against Mycobacterium tuberculosisJournal of Biomolecular Structure & Dynamics202240521892031538-025410.1080/07391102.2020.183572233074049ZhangH.LinG.Microbial proteasomes as drug targetsPLoS Pathogens20211712e10100581553-737410.1371/journal.ppat.101005834882737ArtymiukP.J.A sting in the (N-terminal) tailNature Structural Biology1995212103571072-836810.1038/nsb1295-10358846211PohlC.DikicI.Cellular quality control by the ubiquitin-proteasome system and autophagyScience20193666467818221095-920310.1126/science.aax376931727826GéninE.Reboud-RavauxM.VidalJ.Proteasome inhibitors: recent advances and new perspectives in medicinal chemistryCurrent Topics in Medicinal Chemistry2010103232561873-429410.2174/15680261079072551520166955LeeH.S.JeongG.S.Salinosporamide A, a marine-derived proteasome inhibitor, inhibits T cell activation through regulating proliferation and the cell cycleMolecules (Basel, Switzerland)2020252150311420-304910.3390/molecules2521503133138297Leonardo-SousaC.CarvalhoA.N.GuedesR.A.FernandesP.M.AnicetoN.SalvadorJ.A.Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug ResistanceMolecules (Basel, Switzerland)202227722011420-304910.3390/molecules2707220135408601ZhangX.LinderS.BazzaroM.Drug development targeting the ubiquitin - proteasome system (UPS) for the treatment of human cancersCancers (Basel)20201249022072-669410.3390/cancers1204090232272746StaszczakM.Fungal Secondary Metabolites as Inhibitors of the Ubiquitin-Proteasome SystemInternational Journal of Molecular Sciences20212224133091422-006710.3390/ijms22241330934948102de BettigniesG.CouxO.Proteasome inhibitors: dozens of molecules and still countingBiochimie201092111530451638-618310.1016/j.biochi.2010.06.02320615448ŌmuraS.CrumpA.Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic researchThe Journal of Antibiotics20197241892011881-146910.1038/s41429-019-0141-830755736Krishna-KK.BabyN.RaghuramanR.NavakkodeS.BehnischT.SajikumarS.Regulation of aberrant proteasome activity re-establishes plasticity and long-term memory in an animal model of Alzheimer's diseaseThe FASEB Journal20203479466791530-686010.1096/fj.201902844RR32459037BazouD.LeG.BoyleA.BlumA.O'GormanP.Marizomib: A novel therapeutic approach for the treatment of central nervous system myelomaeJHaem20201131572688-614610.1002/jha2.7235847709WangJ.ShiY.JiangD.β-Lactone Derivatives and Their Anticancer Activities: A Short ReviewCurrent Topics in Medicinal Chemistry202121181645561873-429410.2174/156802662166621040214215033797384Karbalaei-HeidariH.R.PartovifarM.Memarpoor-YazdiM.Evaluation of the bioactive potential of secondary metabolites produced by a new marine micrococcus species isolated from the Persian GulfAvicenna Journal of Medical Biotechnology20201216152008-283532153740AhmadT.AroraP.NalliY.AliA.Riyaz-Ul-HassanS.Antibacterial potential of Juglomycin A isolated from Streptomyces achromogenes, an endophyte of Crocus sativus LinnJournal of Applied Microbiology202012851366771365-267210.1111/jam.1456831883416DharaA.HussainM.S.KanaujiaS.P.KumarM.Acyldepsipeptide activated ClpP1P2 macromolecule of Leptospira, an ideal Achilles' heel to hamper the cell survival and deregulate ClpP proteolytic activityResearch in Microbiology202117221037971769-712310.1016/j.resmic.2021.10379733460738OlsenI.NicholsF.C.Are sphingolipids and serine dipeptide lipids underestimated virulence factors of Porphyromonas gingivalis?Infection and Immunity2018867e00035181098-552210.1128/IAI.00035-1829632248PournejatiR.GustR.Karbalaei-HeidariH.R.An aminoglycoside antibacterial substance, S-137-R, produced by newly isolated Bacillus velezensis strain RP137 from the Persian GulfCurrent Microbiology20197691028371432-099110.1007/s00284-019-01715-731187206RamalingamV.RajaramR.ArchunanG.PadmanabhanP.GulyásB.Structural Characterization, Antimicrobial, Antibiofilm, Antioxidant, Anticancer and Acute Toxicity Properties of N-(2-hydroxyphenyl)-2-phenazinamine From Nocardiopsis exhalans (KP149558)Frontiers in Cellular and Infection Microbiology2022127943382235-298810.3389/fcimb.2022.79433835663469HennessyR.C.DichmannS.I.MartensH.J.ZervasA.StougaardP.Serratia inhibens sp. nov., a new antifungal species isolated from potato (Solanum tuberosum)International Journal of Systematic and Evolutionary Microbiology20207074204111466-503410.1099/ijsem.0.00427032553053MotoyamaT.Secondary metabolites of the rice blast fungus Pyricularia oryzae: biosynthesis and biological functionInternational Journal of Molecular Sciences2020212286981422-006710.3390/ijms2122869833218033SuryawanshiR.K.KoujahL.PatilC.D.AmesJ.M.AgelidisA.YadavalliT.Bacterial pigment prodigiosin demonstrates a unique antiherpesvirus activity that is mediated through inhibition of prosurvival signal transducersJournal of Virology20209413e00251201098-551410.1128/JVI.00251-2032295926DattaS.RajnishK.N.George Priya DossC.Melvin SamuelS.SelvarajanE.ZayedH.Enzyme therapy: a forerunner in catalyzing a healthy society?Expert Opinion on Biological Therapy202020101151741744-768210.1080/14712598.2020.178798032597245GermolecD.R.ShipkowskiK.A.FrawleyR.P.EvansE.Markers of inflammationImmunotoxicity Testing: Methods and Protocols20182018577910.1007/978-1-4939-8549-4_5Immunotoxicity TestingEl-AbdM.A.IbrahimE.A.Production and one-step purification of serratiopeptidase enzyme from Serratia marcescens with potent anti-inflammatory and antioxidant powerEgyptian Pharmaceutical Journal.20201932381687-431510.4103/epj.epj_65_19FolignéB.PléC.TitécatM.DendoovenA.PagnyA.DanielC.Contribution of the gut microbiota in P28GST-mediated anti-inflammatory effects: experimental and clinical insightsCells2019865772073-440910.3390/cells806057731212833JadhavS.B.ShahN.RathiA.RathiV.RathiA.Serratiopeptidase: insights into the therapeutic applicationsBiotechnology Reports (Amsterdam, Netherlands)202028e005442215-017X10.1016/j.btre.2020.e0054433134103MetkarS.K.GirigoswamiA.VijayashreeR.GirigoswamiK.Attenuation of subcutaneous insulin induced amyloid mass in vivo using Lumbrokinase and SerratiopeptidaseInternational Journal of Biological Macromolecules2020163128341879-000310.1016/j.ijbiomac.2020.06.25632615214VachherM.SenA.KapilaR.NigamA.Microbial therapeutic enzymes: A promising area of biopharmaceuticalsCurrent Research in Biotechnology202131952082590-262810.1016/j.crbiot.2021.05.006DasA.DattaS.RocheE.ChaffeeS.JoseE.ShiL.Novel mechanisms of Collagenase Santyl Ointment (CSO) in wound macrophage polarization and resolution of wound inflammationScientific Reports20188116962045-232210.1038/s41598-018-19879-w29374192JeongC.KimS.E.ShimK.S.KimH.J.SongM.H.ParkK.Exploring the in vivo anti-inflammatory actions of simvastatin-loaded porous microspheres on inflamed tenocytes in a collagenase-induced animal model of achilles tendinitisInternational Journal of Molecular Sciences20181938201422-006710.3390/ijms1903082029534523HoyS.M.Collagenase clostridium histolyticum: a review in Peyronie's diseaseClinical Drug Investigation202040183921179-191810.1007/s40261-019-00867-531628593Costa-SilvaT.A.Flores-SantosJ.C.FreireR.K.VitoloM.Pessoa-JrA.Microbial cell disruption methods for efficient release of enzyme L-asparaginasePreparative Biochemistry & Biotechnology2018488707171532-229710.1080/10826068.2018.148785029995576MuneerF.SiddiqueM.H.AzeemF.RasulI.MuzammilS.ZubairM.Microbial L-asparaginase: purification, characterization and applicationsArchives of Microbiology20202025967811432-072X10.1007/s00203-020-01814-132052094JuturuV.WuJ.C.Microbial production of bacteriocins: latest research development and applicationsBiotechnology Advances201836821872001873-189910.1016/j.biotechadv.2018.10.00730385277DriderD.BendaliF.NaghmouchiK.ChikindasM.L.Bacteriocins: not only antibacterial agentsProbiotics and Antimicrobial Proteins201684177821867-131410.1007/s12602-016-9223-027481236KaurS.KaurS.Bacteriocins as potential anticancer agentsFrontiers in Pharmacology201562721663-981210.3389/fphar.2015.0027226617524JooN.E.RitchieK.KamarajanP.MiaoD.KapilaY.L.Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1Cancer Medicine2012132953052045-763410.1002/cam4.3523342279PaivaA.D.de OliveiraM.D.de PaulaS.O.Baracat-PereiraM.C.BreukinkE.MantovaniH.C.Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activityMicrobiology (Reading, England)2012158Pt 11285181465-208010.1099/mic.0.062190-022956757KarpińskiT.M.AdamczakA.Anticancer activity of bacterial proteins and peptidesPharmaceutics2018102541999-492310.3390/pharmaceutics1002005429710857HuangZ.HuH.Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by N-acetylcysteine in Murine MC38 Colorectal Cancer Cells and MDA-MB-231 Human Breast Cancer Cells In VitroMolecules (Basel, Switzerland)20212625111420-304910.3390/molecules2602051133478072RogersL.C.Van TineB.A.Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancersCancer Drug Resistance (Alhambra, Calif.)201923516262578-532X10.20517/cdr.2019.4935582579AngelopoulouA.WardaA.K.HillC.RossR.P.Non-antibiotic microbial solutions for bovine mastitis - live biotherapeutics, bacteriophage, and phage lysinsCritical Reviews in Microbiology2019455-6564801549-782810.1080/1040841X.2019.164838131403343ZaslavskayaM.MakhrovaT.AleksandrovaN.IgnatovaN.BelovaI.TochilinaA.Prospects for using bacteriocins of normal microbiota in antibacterial therapyСовременные технологии в медицине20191131364410.17691/stm2019.11.3.17AslamR.S.AshrafM.MohsinM.IqbalZ.Production and therapeutic potential of bacteriocin produced by indigenous isolates of Bacillus subtilisPakistan Journal of Agricultural Sciences2020575140314110552-9034RadaicA.de JesusM.B.KapilaY.L.Bacterial anti-microbial peptides and nano-sized drug delivery systems: the state of the art toward improved bacteriocinsJournal of Controlled Release2020321100181873-499510.1016/j.jconrel.2020.02.00132035192MokoenaM.P.OmatolaC.A.OlaniranA.O.Applications of lactic acid bacteria and their bacteriocins against food spoilage microorganisms and foodborne pathogensMolecules (Basel, Switzerland)2021262270551420-304910.3390/molecules2622705534834145WalshL.JohnsonC.N.HillC.RossR.P.Efficacy of phage-and bacteriocin-based therapies in combatting nosocomial MRSA infectionsFrontiers in Molecular Biosciences202186540382296-889X10.3389/fmolb.2021.65403833996906YaacobS.N.WahabR.A.MissonM.SabullahM.K.HuyopF.ZinN.M.Lactic acid bacteria and their bacteriocins: new potential weapons in the fight against methicillin-resistant Staphylococcus aureusFuture Microbiology2022179683991746-092110.2217/fmb-2021-025635414206KovalskayaN.Y.HerndonE.E.Foster-FreyJ.A.DonovanD.M.HammondR.W.Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureusAIMS Microbiology201952158752471-188810.3934/microbiol.2019.2.15831384710RahmanM.U.WangW.SunQ.ShahJ.A.LiC.SunY.Endolysin, a promising solution against antimicrobial resistanceAntibiotics (Basel, Switzerland)2021101112772079-638210.3390/antibiotics1011127734827215YuanY.LiX.WangL.LiG.CongC.LiR.The endolysin of the Acinetobacter baumannii phage vB_AbaP_D2 shows broad antibacterial activityMicrobial Biotechnology2021142403181751-791510.1111/1751-7915.1359432519416YuanY.LiX.WangL.LiG.CongC.LiR.The endolysin of the Acinetobacter baumannii phage vB_AbaP_D2 shows broad antibacterial activityMicrobial Biotechnology202114240318KhanF.M.GondilV.S.LiC.JiangM.LiJ.YuJ.A novel Acinetobacter baumannii bacteriophage endolysin LysAB54 with high antibacterial activity against multiple Gram-negative microbesFrontiers in Cellular and Infection Microbiology2021116373132235-298810.3389/fcimb.2021.63731333738267DescampsH.C.HerrmannB.WireduD.ThaissC.A.The path toward using microbial metabolites as therapiesEBioMedicine201944747542352-396410.1016/j.ebiom.2019.05.06331201140CaspaniG.SwannJ.Small talk: microbial metabolites involved in the signaling from microbiota to brainCurrent Opinion in Pharmacology201948991061471-497310.1016/j.coph.2019.08.00131525562Peredo-LovilloA.Romero-LunaH.E.Jiménez-FernándezM.Health promoting microbial metabolites produced by gut microbiota after prebiotics metabolismFood Research International20201361094731873-714510.1016/j.foodres.2020.10947332846558ParkJ.KimC.H.Regulation of common neurological disorders by gut microbial metabolitesExperimental & Molecular Medicine202153121821332092-641310.1038/s12276-021-00703-x34857900HaaseS.WilckN.HaghikiaA.GoldR.MuellerD.N.LinkerR.A.The role of the gut microbiota and microbial metabolites in neuroinflammationEuropean Journal of Immunology202050121863701521-414110.1002/eji.20184780733188704ZhangW.Q.WangY.J.ZhangA.DingY.J.ZhangX.N.JiaQ.J.TMA/TMAO in hypertension: novel horizons and potential therapiesJournal of Cardiovascular Translational Research20211461117241937-539510.1007/s12265-021-10115-x33709384ZhuY.LiQ.JiangH.Gut microbiota in atherosclerosis: focus on trimethylamine N-oxideAPMIS20201285353661600-046310.1111/apm.1303832108960BollongM.J.LeeG.CoukosJ.S.YunH.ZambaldoC.ChangJ.W.A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signallingNature2018562772860041476-468710.1038/s41586-018-0622-030323285KurtzJ.A.VanDusseldorpT.A.DoyleJ.A.OtisJ.S.Taurine in sports and exerciseJournal of the International Society of Sports Nutrition2021181391550-278310.1186/s12970-021-00438-034039357WuG.Important roles of dietary taurine, creatine, carnosine, anserine and 4-hydroxyproline in human nutrition and healthAmino Acids2020523329601438-219910.1007/s00726-020-02823-632072297BaliouS.AdamakiM.IoannouP.PappaA.PanayiotidisM.I.SpandidosD.A.Protective role of taurine against oxidative stress (Review)Molecular Medicine Reports20212421191791-300410.3892/mmr.2021.1224234184084JakariaM.AzamS.HaqueM.E.JoS.H.UddinM.S.KimI.S.Taurine and its analogs in neurological disorders: focus on therapeutic potential and molecular mechanismsRedox Biology2019241012232213-231710.1016/j.redox.2019.10122331141786WenC.LiF.ZhangL.DuanY.GuoQ.WangW.Taurine is involved in energy metabolism in muscles, adipose tissue, and the liverMolecular Nutrition & Food Research2019632e18005361613-413310.1002/mnfr.20180053630251429VahdatM.HosseiniS.A.SoltaniF.CheraghianB.NamjooniaM.The effects of Taurine supplementation on inflammatory markers and clinical outcomes in patients with traumatic brain injury: a double-blind randomized controlled trialNutrition Journal2021201531475-289110.1186/s12937-021-00712-634103066IwegbulemO.WangJ.PfirrmannR.W.RedmondH.P.The role of taurine derivatives in the putative therapy of COVID-19-induced inflammationIrish Journal of Medical Science2022191148561863-436210.1007/s11845-021-02522-533598881ZhuL.LiJ.LiY.IveyK.LeeK.H.EliassenH.Histidine Intake, Human Gut Microbiome, Plasma Levels of Imidazole Propionate, and Coronary Heart Disease Risk in US AdultsCurrent Developments in Nutrition2022610412475-299110.1093/cdn/nzac069.046MolinaroA.Bel LassenP.HenricssonM.WuH.AdriouchS.BeldaE.Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecologyNature Communications20201111102041-172310.1038/s41467-020-19589-w31911652WuB.TanL.WangW.FengX.YanD.Imidazole Propionate is Increased in Diabetes and Associated with Stool ConsistencyDiabetes, Metabolic Syndrome and Obesity2022151715241178-700710.2147/DMSO.S36271535698651van SonJ.SerlieM.J.St\aahlmanM.BäckhedF.NieuwdorpM.Aron-WisnewskyJ.Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese HumansNutrients202113827062072-664310.3390/nu1308270634444866KohA.Manneras-HolmL.YunnN.-O.NilssonP.M.RyuS.H.MolinaroA.Microbial imidazole propionate affects responses to metformin through p38γ-dependent inhibitory AMPK phosphorylationCell metabolism202032464353. e410.1016/j.cmet.2020.07.012HertliS.ZimmermannP.Molecular interactions between the intestinal microbiota and the hostMolecular Microbiology2022117612973071365-295810.1111/mmi.1490535403275ChenY.ChenY.X.Microbiota-Associated Metabolites and Related Immunoregulation in Colorectal CancerCancers (Basel)2021131640542072-669410.3390/cancers1316405434439208FengY.L.CaoG.ChenD.Q.VaziriN.D.ChenL.ZhangJ.Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney diseaseCellular and Molecular Life Sciences201976244961781420-907110.1007/s00018-019-03155-931147751PengQ.WongC.Y.CheukI.W.TeohJ.Y.ChiuP.K.NgC.F.The Emerging Clinical Role of Spermine in Prostate CancerInternational Journal of Molecular Sciences202122943821422-006710.3390/ijms2209438233922247TaoY.TartiaA.LawsonM.ZelinskiM.B.WuW.LiuJ.Y.Can peri-ovulatory putrescine supplementation improve egg quality in older infertile women?Journal of Assisted Reproduction and Genetics20193633954021573-733010.1007/s10815-018-1327-x30467617JucáM.M.Cysne FilhoF.M.de AlmeidaJ.C.MesquitaD.D.BarrigaJ.R.DiasK.C.Flavonoids: biological activities and therapeutic potentialNatural Product Research20203456927051478-642710.1080/14786419.2018.149358830445839OsbornL.J.ClaesenJ.BrownJ.M.Microbial Flavonoid Metabolism: A Cardiometabolic Disease PerspectiveAnnual Review of Nutrition2021411433541545-431210.1146/annurev-nutr-120420-03042434633856UllahA.MunirS.BadshahS.L.KhanN.GhaniL.PoulsonB.G.Important Flavonoids and Their Role as a Therapeutic AgentMolecules (Basel, Switzerland)2020252252431420-304910.3390/molecules2522524333187049BillowriaK.AliR.RangraN.K.KumarR.ChawlaP.A.Bioactive Flavonoids: A Comprehensive Review on Pharmacokinetics and Analytical AspectsCritical Reviews in Analytical Chemistry20221151547-651010.1080/10408347.2022.210564135930461NemethK.PiskulaM.K.Food content, processing, absorption and metabolism of onion flavonoidsCritical Reviews in Food Science and Nutrition20074743974091040-839810.1080/1040839060084629117457724PourováJ.NajmanováI.VopršalováM.MigkosT.PilařováV.ApplováL.Two flavonoid metabolites, 3,4-dihydroxyphenylacetic acid and 4-methylcatechol, relax arteries ex vivo and decrease blood pressure in vivoVascular Pharmacology201811136431879-364910.1016/j.vph.2018.08.00830118763OteizaP.I.FragaC.G.MillsD.A.TaftD.H.Flavonoids and the gastrointestinal tract: local and systemic effectsMolecular Aspects of Medicine2018614191872-945210.1016/j.mam.2018.01.00129317252WangL.GaoM.KangG.HuangH.The potential role of phytonutrients flavonoids influencing gut microbiota in the prophylaxis and treatment of inflammatory bowel diseaseFrontiers in Nutrition202187980382296-861X10.3389/fnut.2021.79803834970585OteizaP.I.FragaC.G.MillsD.A.TaftD.H.Flavonoids and the gastrointestinal tract: local and systemic effectsMolecular Aspects of Medicine2018614191872-945210.1016/j.mam.2018.01.00129317252PerinoA.SchoonjansK.Metabolic Messengers: bile acidsNature Metabolism202244416232522-581210.1038/s42255-022-00559-z35338368RoagerH.M.DragstedL.O.Diet-derived microbial metabolites in health and diseaseNutrition Bulletin2019443216271471-982710.1111/nbu.12396CollinsS.L.StineJ.G.BisanzJ.E.OkaforC.D.PattersonA.D.Bile acids and the gut microbiota: metabolic interactions and impacts on diseaseNature Reviews. Microbiology2023214236471740-153410.1038/s41579-022-00805-x36253479van der SchoorL.W.VerkadeH.J.BertoliniA.de WitS.MennilloE.RettenmeierE.Potential of therapeutic bile acids in the treatment of neonatal HyperbilirubinemiaScientific Reports2021111111072045-232210.1038/s41598-021-90687-534045606CamilleriM.GoresG.J.Therapeutic targeting of bile acidsAmerican Journal of Physiology. Gastrointestinal and Liver Physiology20153094209151522-154710.1152/ajpgi.00121.201526138466LinC.H.KohliR.Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver diseaseClinical and Translational Gastroenterology2018961642155-384X10.1038/s41424-018-0034-329955036EvangelakosI.HeerenJ.VerkadeE.KuipersF.Role of bile acids in inflammatory liver diseasesSeminars in Immunopathology2021434577901863-230010.1007/s00281-021-00869-634236487ArabJ.P.KarpenS.J.DawsonP.A.ArreseM.TraunerM.Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectivesHepatology (Baltimore, Md.)2017651350621527-335010.1002/hep.2870927358174DaiX.HouH.ZhangW.LiuT.LiY.WangS.Microbial metabolites: critical regulators in NAFLDFrontiers in Microbiology2020115676541664-302X10.3389/fmicb.2020.56765433117316ThomasC.GioielloA.NoriegaL.StrehleA.OuryJ.RizzoG.TGR5-mediated bile acid sensing controls glucose homeostasisCell Metabolism2009103167771932-742010.1016/j.cmet.2009.08.00119723493PircherP.C.KittoJ.L.PetrowskiM.L.TangiralaR.K.BischoffE.D.SchulmanI.G.Farnesoid X receptor regulates bile acid-amino acid conjugationThe Journal of Biological Chemistry20032783027703110021-925810.1074/jbc.M30212820012754200StaudingerJ.L.GoodwinB.JonesS.A.Hawkins-BrownD.MacKenzieK.I.LaTourA.The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicityProceedings of the National Academy of Sciences of the United States of America20019863369740027-842410.1073/pnas.05155169811248085KimC.H.Immune regulation by microbiome metabolitesImmunology2018154222091365-256710.1111/imm.1293029569377PengY.NieY.YuJ.WongC.C.Microbial metabolites in colorectal cancer: basic and clinical implicationsMetabolites20211131592218-198910.3390/metabo1103015933802045KissB.MikóE.SeboÉ.TothJ.UjlakiG.SzabóJ.Oncobiosis and microbial metabolite signaling in pancreatic adenocarcinomaCancers (Basel)202012510682072-669410.3390/cancers1205106832344895YangS.LiX.YangF.ZhaoR.PanX.LiangJ.Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic targetFrontiers in Pharmacology20191013601663-981210.3389/fphar.2019.0136031803054GangulyP.PolákJ.VegtN.F. van derHeydaJ.SheaJ.E.Protein stability in TMAO and mixed urea-TMAO solutionsThe Journal of Physical Chemistry B2020124296181971520-520710.1021/acs.jpcb.0c0435732495623CullyM.Microbiome therapeutics go small moleculeNature Reviews. Drug Discovery2019188569721474-178410.1038/d41573-019-00122-831367062DehghanP.FarhangiM.A.NikniazL.NikniazZ.Asghari-JafarabadiM.Gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) potentially increases the risk of obesity in adults: an exploratory systematic review and dose-response meta- analysisObesity Reviews2020215e129931467-789X10.1111/obr.1299332017391JalandraR.DalalN.YadavA.K.VermaD.SharmaM.SinghR.Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancerApplied Microbiology and Biotechnology2021105207651601432-061410.1007/s00253-021-11582-734568962ZhangW.MiikedaA.ZuckermanJ.JiaX.CharugundlaS.ZhouZ.Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in miceScientific Reports20211115182045-232210.1038/s41598-020-80063-033436815GovindarajuluM.PinkyP.D.SteinkeI.BloemerJ.RameshS.KariharanT.Gut metabolite TMAO induces synaptic plasticity deficits by promoting endoplasmic reticulum stressFrontiers in Molecular Neuroscience2020131381662-509910.3389/fnmol.2020.0013832903435JaneiroM.H.RamírezM.J.MilagroF.I.MartínezJ.A.SolasM.Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic TargetNutrients2018101013982072-664310.3390/nu1010139830275434MohanV.K.GeorgeM.A Review of The Contribution of Gut-Dependent Microbiota Derived Marker, Trimethylamine N-oxide (TMAO), in Coronary Artery DiseaseCurrent Research in Nutrition and Food Science202193712212322-000710.12944/CRNFSJ.9.3.01LiuY.Trimethylamine N-oxide generated by the gut microbiota is associated with vascular inflammation: new insights into atherosclerosisMediators of inflammation20202020463417210.1155/2020/4634172CorasR.KavanaughA.BoydT.HuynhD.LagerborgK.A.XuY.J.Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritisClinical and Experimental Rheumatology201937348140392-856X30620278LiuH.JiaK.RenZ.SunJ.PanL.L.PRMT5 critically mediates TMAO-induced inflammatory response in vascular smooth muscle cellsCell Death & Disease20221342992041-488910.1038/s41419-022-04719-735379776WangJ.GuX.YangJ.WeiY.ZhaoY.Gut microbiota dysbiosis and increased plasma LPS and TMAO levels in patients with preeclampsiaFrontiers in Cellular and Infection Microbiology201994092235-298810.3389/fcimb.2019.0040931850241HarrisH.C.MorrisonD.J.EdwardsC.A.Impact of the source of fermentable carbohydrate on SCFA production by human gut microbiota in vitro - a systematic scoping review and secondary analysisCritical Reviews in Food Science and Nutrition2021612238929031549-785210.1080/10408398.2020.180999132865002BloomP.P.TapperE.B.YoungV.B.LokA.S.Microbiome therapeutics for hepatic encephalopathyJournal of Hepatology20217561452641600-064110.1016/j.jhep.2021.08.00434453966RoyR.Nguyen-NgoC.LappasM.Short-chain fatty acids as novel therapeutics for gestational diabetesJournal of Molecular Endocrinology202065221341479-681310.1530/JME-20-009432580157SinghD.GuptaS.VermaI.MorsyM.A.NairA.B.AhmedA.F.Hidden pharmacological activities of valproic acid: A new insightBiomedicine and Pharmacotherapy20211421120211950-600710.1016/j.biopha.2021.11202134463268LipskaK.GumieniczekA.FilipA.A.Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: possibilities and challengesActa Pharmaceutica (Zagreb, Croatia)20207032913011846-955810.2478/acph-2020-002132074065ParkH.K.HanB.R.ParkW.H.Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell deathInternational Journal of Molecular Sciences202021726491422-006710.3390/ijms2107264932290325IgunnuA.OmotehinseA.DavidI.OgunsolaO.OyegokeR.Valproic acid displays anti-diabetic and pro-antioxidant effects in high-fat diet and streptozotocin-induced type 2 diabetic ratsNigerian Journal of Pure & Applied Science201932332436ZhangL.LiuC.JiangQ.YinY.Butyrate in energy metabolism: there is still more to learnTrends in Endocrinology and Metabolism2021323159691879-306110.1016/j.tem.2020.12.00333461886FuX.LiuZ.ZhuC.MouH.KongQ.Nondigestible carbohydrates, butyrate, and butyrate-producing bacteriaCritical reviews in food science nutrition201959sup1S130S5210.1080/10408398.2018.1542587MagnussonM.K.IsakssonS.ÖhmanL.The anti-inflammatory immune regulation induced by butyrate is impaired in inflamed intestinal mucosa from patients with ulcerative colitisInflammation2020432507171573-257610.1007/s10753-019-01133-831797122GiacobbeJ.BenoitonB.ZunszainP.ParianteC.M.BorsiniA.The anti-inflammatory role of omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative, and neurological disordersFrontiers in Psychiatry2020111221664-064010.3389/fpsyt.2020.0012232180741FadallahM.ZahranM.H.El-AssmyA.M.BarakatN.M.KhaterS.AwadallaA.Omega-3 polyunsaturated fatty acids: a modified approach for chemo-prevention of bladder cancer in a rat model and molecular studies of antineoplastic mechanismsMolecular Biology Reports20224976357651573-497810.1007/s11033-022-07445-735467177TadicM.SalaC.GrassiG.ManciaG.TaddeiS.RottbauerW.Omega-3 fatty acids and coronary artery disease: more questions than answersJournal of Clinical Medicine2021101124952077-038310.3390/jcm1011249534200081ChitreN.M.MoniriN.H.MurnaneK.S.Omega-3 fatty acids as druggable therapeutics for neurodegenerative disordersCNS & Neurological Disorders - Drug Targets20191810735491996-318110.2174/187152731866619111409374931724519MalekahmadiM.PahlavaniN.FirouziS.IslamS.M.ZonoozS.R.MoghaddamO.M.The Effect of Immunomodulatory Diet (Omega-3 Fatty Acid, γ-Linolenic Acid and Antioxidants) on clinical outcomes in critically ill patientsAuthorea2020preprint10.22541/au.158465450.06651823BazinetR.P.MetherelA.H.ChenC.T.ShaikhS.R.NadjarA.JoffreC.Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depressionBrain, Behavior, and Immunity2020852181090-213910.1016/j.bbi.2019.07.00131278982ChangJ.P.SuK.P.MondelliV.SatyanarayananS.K.YangH.T.ChiangY.J.High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levelsTranslational Psychiatry2019913032158-318810.1038/s41398-019-0633-031745072NelsonJ.R.RaskinS.The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular diseasePostgraduate Medicine20191314268771941-926010.1080/00325481.2019.160741431063407den HartighL.J.Conjugated Linoleic Acid Effects on Cancer, Obesity, and Atherosclerosis: A Review of Pre-Clinical and Human Trials with Current PerspectivesNutrients20191123702072-664310.3390/nu1102037030754681DachevM.BryndováJ.JakubekM.Mou\vckaZ.UrbanM.The effects of conjugated linoleic acids on cancerProcesses (Basel, Switzerland)2021934542227-971710.3390/pr9030454EphraimE.JewellD.The Influence of Fiber Source on Circulating Concentration of Age-Related Metabolites and the Gut Microbial Composition in Senior CatsCurrent Developments in Nutrition20215132475-299110.1093/cdn/nzab033_013NeedhamB.D.FunabashiM.AdameM.D.WangZ.BoktorJ.C.HaneyJ.A gut-derived metabolite alters brain activity and anxiety behaviour in miceNature20226027898647531476-468710.1038/s41586-022-04396-835165440KangD.W.AdamsJ.B.VargasonT.SantiagoM.HahnJ.Krajmalnik-BrownR.Distinct fecal and plasma metabolites in children with autism spectrum disorders and their modulation after microbiota transfer therapyMSphere202055e00314202379-504210.1128/mSphere.00314-2033087514